公开(公告)号：US20220002432A1

公开(公告)日：2022-01-06

申请号：US17293258

申请日：2019-11-15

Applicant: Virtuoso BINco, Inc. ,  The Regents of the University of California

Inventor： Bin LIU ,  Xiaocheng CHEN ,  Scott BIDLINGMAIER ,  Leonard POST ,  Yang SU ,  Namkyung LEE

IPC: C07K16/28 ,  A61K45/06

Abstract: Disclosed herein are anti-CD38 antibodies, anti-ICAM1 antibodies, pharmaceutical compositions comprising anti-CD38 antibodies and/or anti-ICAM1 antibodies, and methods of use for the treatment of a proliferative disease. In certain embodiments, also disclosed herein are multi-specific antibodies (e.g., bispecific antibodies) comprising a first targeting moiety that specifically binds to CD38 and a second targeting moiety that specifically binds to ICAM1, pharmaceutical compositions comprising the multi-specific antibodies, and methods of use for the treatment of a proliferative disease.

公开(公告)号：US20240254219A1

公开(公告)日：2024-08-01

申请号：US18693416

申请日：2022-09-20

Applicant: The Regents of the University of California

Inventor： Bin LIU ,  Nam-Kyung LEE ,  Scott BIDLINGMAIER ,  Yang SU

IPC: C07K16/28 ,  A61K39/00 ,  A61P19/10 ,  C12N15/10

CPC classification number: C07K16/28 ,  A61P19/10 ,  C12N15/1037 ,  C12N15/1055 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/75

Abstract: Antibodies are provided herein that agonize Wnt signaling, do not compete with a Wnt ligand for LRP6 binding, and activate Wnt signaling in the presence of inhibitors. Methods for promoting cell differentiation and tissue regeneration using the disclosed antibodies are also provided.

公开(公告)号：US20220411508A1

公开(公告)日：2022-12-29

申请号：US17639225

申请日：2020-09-09

Applicant: The Regents of the University of California

Inventor： Bin LIU ,  Shanshan LANG ,  Yang SU ,  Scott BIDLINGMAIER ,  Nam-Kyung LEE

IPC: C07K16/28

Abstract: The present disclosure relates generally to compositions and methods useful for the production of engineered antibodies having (i) multiple antigen-binding specificities and (ii) Fc regions that have been modified to promote heterodimer formation between heavy chains from antibodies with different specificities. Also provided are recombinant cells, recombinant nucleic acids encoding such engineered antibodies, as well as pharmaceutical compositions containing same.

公开(公告)号：US20160096883A1

公开(公告)日：2016-04-07

申请号：US14836734

申请日：2015-08-26

Applicant: The Regents of the University of California

Inventor： Bin LIU ,  James D. MARKS ,  Xiaodong ZHU ,  Scott BIDLINGMAIER

IPC: C07K16/18 ,  A61K47/48 ,  G01N33/574 ,  A61K51/10

CPC classification number: C07K16/18 ,  A61K47/6843 ,  A61K51/1045 ,  C07K16/2896 ,  C07K16/3053 ,  C07K2317/21 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/77 ,  C07K2317/92 ,  C12N5/0695 ,  G01N33/57407

Abstract: The present disclosure is generally related to antibodies that bind specifically to glioblastoma multiforme (GBM) cells. In particular, the present disclosure provides compositions comprising human single chain or full-length antibodies that bind tumor cells. Additionally the present disclosure provides methods of using the anti-GBM antibodies.

Abstract translation: 本公开通常涉及特异性结合多形性胶质母细胞瘤（GBM）细胞的抗体。 特别地，本公开提供了包含结合肿瘤细胞的人单链或全长抗体的组合物。 另外，本公开提供了使用抗GBM抗体的方法。

公开(公告)号：US20240374748A1

公开(公告)日：2024-11-14

申请号：US18666551

申请日：2024-05-16

Applicant: The Regents of the University of California

Inventor： Bin LIU ,  Scott BIDLINGMAIER ,  Yang SU

IPC: A61K47/68 ,  A61K35/00 ,  A61K35/17 ,  A61K39/00 ,  A61P35/00 ,  C07K16/28 ,  C07K16/40 ,  C12N9/16 ,  G01N33/574

Abstract: This invention provides antibodies directed against a highly specific and previously unrecognized marker for cancerous cells. In certain embodiments an isolated antibody or fragment thereof that specifically binds human placentally expressed ALPP and/or ALPPL2, but not ALPL and ALPI that are expressed outside the placenta is provided as well as immunoconjugates comprising such antibodies.

公开(公告)号：US20240076399A1

公开(公告)日：2024-03-07

申请号：US18183042

申请日：2023-03-13

Applicant: The Regents of the University of California

Inventor： Bin LIU ,  Namkyung LEE ,  Yang SU ,  Scott BIDLINGMAIER

IPC: C07K16/30 ,  A61K31/713 ,  C07K16/28 ,  C07K16/46

CPC classification number: C07K16/30 ,  A61K31/713 ,  C07K16/2821 ,  C07K16/2866 ,  C07K16/468 ,  C07K2317/31 ,  C07K2317/622 ,  C07K2317/64 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92

Abstract: The present disclosure relates to an engineered antibody that co-engages a cell type-selective (or specific) antigen (guide) and a signaling receptor (effector) on a target cell. In some instances, the engineered antibody is capable of modulating a signaling pathway on a target cell. In other embodiments, an engineered antibody of the present disclosure is administered to a subject for the treatment of a disease or condition.

公开(公告)号：US20190330365A1

公开(公告)日：2019-10-31

申请号：US16349958

申请日：2017-11-17

Applicant: The Regents of the University of California

Inventor： Bin LIU ,  Nam-Kyung LEE ,  Yang SU ,  Scott BIDLINGMAIER

IPC: C07K16/30 ,  A61K31/713 ,  C07K16/28 ,  C07K16/46

Abstract: The present disclosure relates to an engineered antibody that co-engages a cell type-selective (or specific) antigen (guide) and a signaling receptor (effector) on a target cell. In some instances, the engineered antibody is capable of modulating a signaling pathway on a target cell. In other embodiments, an engineered antibody of the present disclosure is administered to a subject for the treatment of a disease or condition.